Two biologics studied for multiple myeloma

Mar 14, 2007

U.S. medical scientists report investigating two novel biologics for their potential benefit to multiple myeloma patients.

The separate clinical trials are being conducted at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

A Phase 2 trial with VEGF Trap will assess the drug's ability to slow tumor growth in patients with multiple myeloma. VEGF Trap is a recombinant human fusion protein that binds VEGF, a key molecule in tumor blood-vessel growth (angiogenesis).

The other investigation is a Phase 1 trial of hLL1, a humanized monoclonal antibody that has shown significant growth inhibition of multiple myeloma and B-lymphoma cells in preclinical studies.

"These two exciting antibody trials may give new hope to myeloma patients with relapsed and refractory disease," said Dr. Ruben Niesvizky, principal investigator of both studies.

Multiple myeloma is a blood cancer that causes white blood cells to become malignant and attack the body's bones, resulting in painful fractures, kidney failure and death. The disease affects an estimated 40,000 Americans annually.

Copyright 2007 by United Press International

Explore further: Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Gene mutation discovered in blood disorder

3 minutes ago

An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells. Studying a family in which ...

Airway muscle-on-a-chip mimics asthma

2 hours ago

The majority of drugs used to treat asthma today are the same ones that were used 50 years ago. New drugs are urgently needed to treat this chronic respiratory disease, which causes nearly 25 million people ...

Lost protein could prevent hardening of the arteries

5 hours ago

(Medical Xpress)—Researchers have found that when the protein matrix metalloproteinase-14 (MMP-14) is reduced or lost, white blood cells, known as macrophages, become good and could prevent hardening of ...

User comments : 0